AA
SNDX icon

AlphaCentric Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

AlphaCentric Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$3K – 175
2020
Q2 		$3K Buy
+200
New +$3.05K ﹤0.01% 143

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

AlphaCentric Advisors's SNDX Position: Q3 2020 in Review

AlphaCentric Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q3 2020, closing a stake of 200 shares — an estimated $3K sold.

AlphaCentric Advisors first reported a position in SNDX in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 99 funds tracked by Wall St. Rank hold SNDX as of Q3 2020.

  • AlphaCentric Advisors reported no remaining Syndax Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • AlphaCentric Advisors sold 200 Syndax Pharmaceuticals shares in Q3 2020, an estimated $3K.
  • AlphaCentric Advisors first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • AlphaCentric Advisors's Syndax Pharmaceuticals position peaked at $3K in Q2 2020.
  • 99 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2020.

Based on AlphaCentric Advisors's 13F filing for Q3 2020, filed 11 Mar 2022.